azacitidine,sndx-5613,enasidenib,revumenib,venetoclax
syndax pharma,servier,roche,abbvie
['revumenib', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'sndx-5613', 'beat aml']
privileged to lead &amp; present our trial in progress of aza/ven/sndx-5613 (revumenib) in newly dx older/unfit aml with mll or npm1 mut on behalf of the beat aml consortium. come by our poster monday evening . #ash22 
Associate Prof of Med @UNC_Lineberger | Oncologist | Clinical Trialist- #AML & #MDS | Alum of Osler Residency & Hopkins Oncology | Diehard NYG fan| Views my own